Trial Profile
Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms CHORUS
- Sponsors Astellas Pharma Europe Ltd
- 10 Nov 2022 Status changed from active, no longer recruiting to completed.
- 26 Feb 2021 Planned End Date changed from 1 Oct 2022 to 31 Oct 2022.
- 26 Feb 2021 Planned primary completion date changed from 1 Oct 2022 to 31 Oct 2022.